-+ 0.00%
-+ 0.00%
-+ 0.00%

ARRIVENT BIOPHARMA SHARES DOWN 62.4% PREMARKET AFTER CO'S LUNG CANCER THERAPY FAILS LATE-STAGE TRIAL

Reuters·10/06/2026 12:38:26